{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:14:09Z","timestamp":1768565649889,"version":"3.49.0"},"posted":{"date-parts":[[2023,7,12]]},"group-title":"Addiction Medicine","reference-count":87,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,7,12]]},"abstract":"<jats:title>Abstract\/Summary<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The risk for cannabis use disorder (CUD) is elevated among U.S. adults with chronic pain, and CUD rates are disproportionately increasing in this group. Little is known about the role of medical cannabis laws (MCL) and recreational cannabis laws (RCL) in these increases. Among U.S. Veterans Health Administration (VHA) patients, we examined whether MCL and RCL effects on CUD prevalence differed between patients with and without chronic pain.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with \u22651 primary care, emergency, or mental health visit to the VHA and no hospice\/palliative care within a given calendar year, 2005-2019 (yearly n=3,234,382 to 4,579,994) were analyzed using VHA electronic health record (EHR) data. To estimate the role of MCL and RCL enactment in the increases in prevalence of diagnosed CUD and whether this differed between patients with and without chronic pain, staggered-adoption difference-in-difference analyses were used, fitting a linear binomial regression model with fixed effects for state, categorical year, time-varying cannabis law status, state-level sociodemographic covariates, a chronic pain indicator, and patient covariates (age group [18-34, 35-64; 65-75], sex, and race and ethnicity). Pain was categorized using an American Pain Society taxonomy of painful medical conditions.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>In patients with chronic pain, enacting MCL led to a 0\u00b714% (95% CI=0\u00b712%-0\u00b715%) absolute increase in CUD prevalence, with 8\u00b74% of the total increase in CUD prevalence in MCL-enacting states attributable to MCL. Enacting RCL led to a 0\u00b719% (95%CI: 0\u00b716%, 0\u00b722%) absolute increase in CUD prevalence, with 11\u00b75% of the total increase in CUD prevalence in RCL-enacting states attributable to RCL. In patients without chronic pain, enacting MCL and RCL led to smaller absolute increases in CUD prevalence (MCL: 0\u00b7037% [95%CI: 0\u00b703, 0\u00b705]; RCL: 0\u00b7042% [95%CI: 0\u00b702, 0\u00b706]), with 5\u00b77% and 6\u00b70% of the increases in CUD prevalence attributable to MCL and RCL. Overall, MCL and RCL effects were significantly greater in patients with than without chronic pain. By age, MCL and RCL effects were negligible in patients age 18-34 with and without pain. In patients age 35-64 with and without pain, MCL and RCL effects were significant (p&lt;0.001) but small. In patients age 65-75 with pain, absolute increases were 0\u00b710% in MCL-only states and 0\u00b722% in MCL\/RCL states, with 9\u00b73% of the increase in CUD prevalence in MCL-only states attributable to MCL, and 19.4% of the increase in RCL states attributable to RCL. In patients age 35-64 and 65-75, MCL and RCL effects were significantly greater in patients with pain.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Interpretation<\/jats:title>\n                  <jats:p>In patients age 35-75, the role of MCL and RCL in the increasing prevalence of CUD was greater in patients with chronic pain than in those without chronic pain, with particularly pronounced effects in patients with chronic pain age 65-75. Although the VHA offers extensive behavioral and non-opioid pharmaceutical treatments for pain, cannabis may seem a more appealing option given media enthusiasm about cannabis, cannabis commercialization activities, and widespread public beliefs about cannabis efficacy. Cannabis does not have the risk\/mortality profile of opioids, but CUD is a clinical condition with considerable impairment and comorbidity. Because cannabis legalization in the U.S. is likely to further increase, increasing CUD prevalence among patients with chronic pain following state legalization is a public health concern. The risk of chronic pain increases as individuals age, and the average age of VHA patients and the U.S. general population is increasing. Therefore, clinical monitoring of cannabis use and discussion of the risk of CUD among patients with chronic pain is warranted, especially among older patients.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Research in Context<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Evidence before this study<\/jats:title>\n                    <jats:p>Only three studies have examined the role of state medical cannabis laws (MCL) and\/or recreational cannabis laws (RCL) in the increasing prevalence of cannabis use disorder (CUD) in U.S. adults, finding significant MCL and RCL effects but with modest effect sizes. Effects of MCL and RCL may vary across important subgroups of the population, including individuals with chronic pain. PubMed was searched by DH for publications on U.S. time trends in cannabis legalization, cannabis use disorders (CUD) and pain from database inception until March 15, 2023, without language restrictions. The following search terms were used: (medical cannabis laws) AND (pain) AND (cannabis use disorder); (recreational cannabis laws) AND (pain) AND (cannabis use disorder); (cannabis laws) AND (pain) AND (cannabis use disorder). Only one study was found that had CUD as an outcome, and this study used cross-sectional data from a single year, which cannot be used to determine trends over time. Therefore, evidence has been lacking on whether the role of state medical and recreational cannabis legalization in the increasing US adult prevalence of CUD differed by chronic pain status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Added value of this study<\/jats:title>\n                    <jats:p>To our knowledge, this is the first study to examine whether the effects of state MCL and RCL on the nationally increasing U.S. rates of adult cannabis use disorder differ by whether individuals experience chronic pain or not. Using electronic medical record data from patients in the Veterans Health Administration (VHA) that included extensive information on medical conditions associated with chronic pain, the study showed that the effects of MCL and RCL on the prevalence of CUD were stronger among individuals with chronic pain age 35-64 and 65-75, an effect that was particularly pronounced in older patients ages 65-75.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications of all the available evidence<\/jats:title>\n                    <jats:p>MCL and RCL are likely to influence the prevalence of CUD through commercialization that increases availability and portrays cannabis use as \u2018normal\u2019 and safe, thereby decreasing perception of cannabis risk. In patients with pain, the overall U.S. decline in prescribed opioids may also have contributed to MCL and RCL effects, leading to substitution of cannabis use that expanded the pool of individuals vulnerable to CUD. The VHA offers extensive non-opioid pain programs. However, positive media reports on cannabis, positive online \u201cinformation\u201d that can sometimes be misleading, and increasing popular beliefs that cannabis is a useful prevention and treatment agent may make cannabis seem preferable to the evidence-based treatments that the VHA offers, and also as an easily accessible option among those not connected to a healthcare system, who may face more barriers than VHA patients in accessing non-opioid pain management. When developing cannabis legislation, unintended consequences should be considered, including increased risk of CUD in large vulnerable subgroups of the population.<\/jats:p>\n                  <\/jats:sec>\n                <\/jats:sec>","DOI":"10.1101\/2023.07.10.23292453","type":"posted-content","created":{"date-parts":[[2023,7,14]],"date-time":"2023-07-14T06:25:30Z","timestamp":1689315930000},"source":"Crossref","is-referenced-by-count":2,"title":["Chronic Pain, Cannabis Legalization and Cannabis Use Disorder in Veterans Health Administration Patients, 2005 to 2019"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6533-7021","authenticated-orcid":false,"given":"Deborah S.","family":"Hasin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie M.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Alschuler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary L.","family":"Mannes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Malte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Olfson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine M.","family":"Keyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaimie L.","family":"Gradus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Cerd\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles C.","family":"Maynard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salomeh","family":"Keyhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia S.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofir","family":"Livne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoanna","family":"McDowell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Saxon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023071701351345000_2023.07.10.23292453v1.1","unstructured":"Martinovic J. European Cannabis News: These Countries Prep For Legalization, UK Official Calls Pot As Harmful As Heroin: Benzinga; 2023 [Available from: https:\/\/www.benzinga.com\/markets\/cannabis\/23\/01\/30568247\/european-cannabis-news-these-countries-prep-for-legalization-uk-official-calls-pot-as-harmful-as."},{"key":"2023071701351345000_2023.07.10.23292453v1.2","unstructured":"Cannabis Act: Government of Canada; 2023 [Available from: https:\/\/laws-lois.justice.gc.ca\/eng\/annualstatutes\/2018_16\/page-1.html."},{"issue":"7","key":"2023071701351345000_2023.07.10.23292453v1.3","doi-asserted-by":"crossref","first-page":"e222018","DOI":"10.1001\/jamahealthforum.2022.2018","article-title":"California Cannabis Markets-Why Industry-Friendly Regulation Is Not Good Public Health","volume":"3","year":"2022","journal-title":"JAMA Health Forum"},{"key":"2023071701351345000_2023.07.10.23292453v1.4","doi-asserted-by":"crossref","first-page":"106479","DOI":"10.1016\/j.addbeh.2020.106479","article-title":"What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis","volume":"109","year":"2020","journal-title":"Addict Behav"},{"key":"2023071701351345000_2023.07.10.23292453v1.5","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"Pt B","key":"2023071701351345000_2023.07.10.23292453v1.6","first-page":"109137","article-title":"Psychosocial and health problems associated with alcohol use disorder and cannabis use disorder in U.S","volume":"229","year":"2021","journal-title":"adults. Drug Alcohol Depend"},{"issue":"6","key":"2023071701351345000_2023.07.10.23292453v1.7","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1176\/appi.ajp.2015.15070907","article-title":"Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III","volume":"173","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"10","key":"2023071701351345000_2023.07.10.23292453v1.8","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/S2215-0366(16)30208-5","article-title":"Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys","volume":"3","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"2023071701351345000_2023.07.10.23292453v1.9","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1111\/jgs.17213","article-title":"Decreasing perceived risk associated with regular cannabis use among older adults in the United States from 2015 to 2019","volume":"69","year":"2021","journal-title":"J Am Geriatr Soc"},{"key":"2023071701351345000_2023.07.10.23292453v1.10","doi-asserted-by":"crossref","first-page":"107468","DOI":"10.1016\/j.drugalcdep.2019.05.008","article-title":"Cannabis use disorders among adults in the United States during a time of increasing use of cannabis","volume":"204","year":"2019","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"2023071701351345000_2023.07.10.23292453v1.11","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/jamapsychiatry.2015.1858","article-title":"Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013","volume":"72","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"2023071701351345000_2023.07.10.23292453v1.12","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/00952990.2019.1569668","article-title":"Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: a narrative review and new findings","volume":"45","year":"2019","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"1","key":"2023071701351345000_2023.07.10.23292453v1.13","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1080\/08897077.2021.1944956","article-title":"Time-trends in hospitalizations with cannabis use disorder: A 17-year U.S","volume":"43","year":"2022","journal-title":"national study. Subst Abus"},{"key":"2023071701351345000_2023.07.10.23292453v1.14","doi-asserted-by":"publisher","DOI":"10.1037\/a0027622"},{"key":"2023071701351345000_2023.07.10.23292453v1.15","doi-asserted-by":"crossref","unstructured":"Hasin DS , Saxon AJ , Malte C , Olfson M , Keyes KM , Gradus JL , et al. Trends in Cannabis Use Disorder Diagnoses in the U.S. Veterans Health Administration, 2005-2019. Am J Psychiatry. 2022:appiajp22010034.","DOI":"10.1176\/appi.ajp.22010034"},{"key":"2023071701351345000_2023.07.10.23292453v1.16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drugalcdep.2016.10.004","article-title":"State-level medical marijuana laws, marijuana use and perceived availability of marijuana among the general U.S","volume":"169","year":"2016","journal-title":"population. Drug Alcohol Depend"},{"issue":"6","key":"2023071701351345000_2023.07.10.23292453v1.17","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1111\/add.15795","article-title":"A difference-in-difference approach to examining the impact of cannabis legalization on disparities in the use of cigarettes and cannabis in the United States, 2004-17","volume":"117","year":"2022","journal-title":"Addiction"},{"key":"2023071701351345000_2023.07.10.23292453v1.18","doi-asserted-by":"crossref","first-page":"108364","DOI":"10.1016\/j.drugalcdep.2020.108364","article-title":"Impact of state-level cannabis legalization on poly use of alcohol and cannabis in the United States, 2004-2017","volume":"218","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"2023071701351345000_2023.07.10.23292453v1.19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/add.16016","article-title":"Impacts of recreational cannabis legalization on cannabis use: a longitudinal discordant twin study","volume":"118","year":"2023","journal-title":"Addiction"},{"issue":"10","key":"2023071701351345000_2023.07.10.23292453v1.20","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1111\/add.15895","article-title":"Recreational cannabis legalization and transitions in cannabis use: findings from a nationally representative longitudinal cohort in the United States","volume":"117","year":"2022","journal-title":"Addiction"},{"issue":"9","key":"2023071701351345000_2023.07.10.23292453v1.21","doi-asserted-by":"crossref","first-page":"e2127002","DOI":"10.1001\/jamanetworkopen.2021.27002","article-title":"Racial and Ethnic Differences in Cannabis Use Following Legalization in US States With Medical Cannabis Laws","volume":"4","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2023071701351345000_2023.07.10.23292453v1.22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jamapsychiatry.2019.3254","article-title":"Association Between Recreational Marijuana Legalization in the United States and Changes in Marijuana Use and Cannabis Use Disorder From 2008 to 2016","volume":"77","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"2023071701351345000_2023.07.10.23292453v1.23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1001\/jamapsychiatry.2017.0724","article-title":"US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws: 1991-1992 to 2012-2013","volume":"74","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"2023071701351345000_2023.07.10.23292453v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2015.03.007"},{"key":"2023071701351345000_2023.07.10.23292453v1.25","unstructured":"Hasin DS , Wall MM , Choi CJ , Alschuler DM , Malte C , Olfson M , et al. State Cannabis Legalization and Increases in Cannabis Use Disorder in the U.S. Veterans Health Administration, 2005 to 2019. JAMA Psychiatry. In Press."},{"key":"2023071701351345000_2023.07.10.23292453v1.26","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001384"},{"key":"2023071701351345000_2023.07.10.23292453v1.27","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002291"},{"issue":"3","key":"2023071701351345000_2023.07.10.23292453v1.28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jpain.2016.10.021","article-title":"Severe Pain in Veterans: The Effect of Age and Sex, and Comparisons With the General Population","volume":"18","year":"2017","journal-title":"J Pain"},{"issue":"12","key":"2023071701351345000_2023.07.10.23292453v1.29","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.jpain.2022.08.002","article-title":"The Geography of Pain in the United States and Canada","volume":"23","year":"2022","journal-title":"J Pain"},{"issue":"2","key":"2023071701351345000_2023.07.10.23292453v1.30","first-page":"436","article-title":"Persistent, Consistent, and Extensive: The Trend of Increasing Pain Prevalence in Older Americans","volume":"75","year":"2020","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"key":"2023071701351345000_2023.07.10.23292453v1.31","doi-asserted-by":"publisher","DOI":"10.1007\/s13142-011-0094-3"},{"issue":"7","key":"2023071701351345000_2023.07.10.23292453v1.32","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/appi.ajp.2019.19030284","article-title":"U.S. Adults With Pain, a Group Increasingly Vulnerable to Nonmedical Cannabis Use and Cannabis Use Disorder: 2001-2002 and 2012-2013","volume":"177","year":"2020","journal-title":"Am J Psychiatry"},{"issue":"2","key":"2023071701351345000_2023.07.10.23292453v1.33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/j.pain.0000000000002345","article-title":"Pain, cannabis use, and physical and mental health indicators among veterans and nonveterans: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III","volume":"163","year":"2022","journal-title":"Pain"},{"key":"2023071701351345000_2023.07.10.23292453v1.34","unstructured":"Mannes ZL , Malte C , Olfson M , Keyes KM , Martins SS , Cerda M , et al. Increasing risk of cannabis use disorder among U.S. veterans with chronic pain: 2005-2019. Pain. In press."},{"issue":"1","key":"2023071701351345000_2023.07.10.23292453v1.35","doi-asserted-by":"crossref","first-page":"e2249797","DOI":"10.1001\/jamanetworkopen.2022.49797","article-title":"Use of Cannabis and Other Pain Treatments Among Adults With Chronic Pain in US States With Medical Cannabis Programs","volume":"6","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2023071701351345000_2023.07.10.23292453v1.36","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/ADM.0000000000000593","article-title":"Differences in Opinions About Marijuana Use and Prevalence of Use by State Legalization Status","volume":"14","year":"2020","journal-title":"J Addict Med"},{"issue":"11","key":"2023071701351345000_2023.07.10.23292453v1.37","doi-asserted-by":"crossref","first-page":"e2243848","DOI":"10.1001\/jamanetworkopen.2022.43848","article-title":"Placebo Response and Media Attention in Randomized Clinical Trials Assessing Cannabis-Based Therapies for Pain: A Systematic Review and Meta-analysis","volume":"5","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2023071701351345000_2023.07.10.23292453v1.38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00406-018-0960-9","article-title":"Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain","volume":"269","year":"2019","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2023071701351345000_2023.07.10.23292453v1.39","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001293"},{"issue":"7","key":"2023071701351345000_2023.07.10.23292453v1.40","first-page":"945","article-title":"U.S","volume":"175","year":"2022","journal-title":"Trends in Registration for Medical Cannabis and Reasons for Use From 2016 to 2020 : An Observational Study. Ann Intern Med"},{"key":"2023071701351345000_2023.07.10.23292453v1.41","unstructured":"U.S. Department of Veteran Affairs. About VHA 2022 [Available from: https:\/\/www.va.gov\/health\/aboutvha.asp."},{"key":"2023071701351345000_2023.07.10.23292453v1.42","unstructured":"U.S. Department of Veteran Affairs. Expenditures 2022 [Available from: https:\/\/www.va.gov\/vetdata\/expenditures.asp."},{"issue":"8","key":"2023071701351345000_2023.07.10.23292453v1.43","doi-asserted-by":"crossref","first-page":"e2228088","DOI":"10.1001\/jamanetworkopen.2022.28088","article-title":"Content Analysis of the Corporate Social Responsibility Practices of 9 Major Cannabis Companies in Canada and the US","volume":"5","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2023071701351345000_2023.07.10.23292453v1.44","unstructured":"PainCondition_ICD9CM_ICD10CM_Crosswalk: GitHub, Inc.; [Available from: https:\/\/github.com\/PainResearch\/PainCondition_ICD9CM_ICD10CM_Crosswalk."},{"key":"2023071701351345000_2023.07.10.23292453v1.45","unstructured":"RAND Corporation. OPTIC-Vetted Policy Data Sets: RAND Corporation; 2022 [Available from: https:\/\/www.rand.org\/health-care\/centers\/optic\/resources\/datasets.html."},{"key":"2023071701351345000_2023.07.10.23292453v1.46","unstructured":"United States Census Bureau. American Community Survey 1-Year Data (2005-2008) 2022 [Available from: https:\/\/www.census.gov\/data\/developers\/data-sets\/acs-5year.html."},{"key":"2023071701351345000_2023.07.10.23292453v1.47","unstructured":"United States Census Bureau. American Community Survey 1-Year Data (2009-2019) 2022 [Available from: https:\/\/www.census.gov\/data\/developers\/data-sets\/acs-5year.html."},{"key":"2023071701351345000_2023.07.10.23292453v1.48","unstructured":"Walker K , Herman M. tidycensus: Load US Census Boundary and Attribute Data as \u2018tidyverse\u2019 and \u2018sf\u2019-Ready Data Frames. R package version 1.2.3 ed2022."},{"issue":"1","key":"2023071701351345000_2023.07.10.23292453v1.49","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jeconom.2020.10.012","article-title":"Design-based analysis in Difference-In-Differences settings with staggered adoption","volume":"226","year":"2022","journal-title":"J Econom"},{"key":"2023071701351345000_2023.07.10.23292453v1.50","unstructured":"Hasin D , Saxon A , Malte C , Olfson M , Keyes K , Gradus J , et al. Trends in Cannabis Use Disorder Diagnoses in the U.S. Veterans Health Administration: 2005-2019. in press."},{"issue":"12","key":"2023071701351345000_2023.07.10.23292453v1.51","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/add.13945","article-title":"Potency increase, product development and marijuana marketing in times of legalization","volume":"112","year":"2017","journal-title":"Addiction"},{"issue":"23","key":"2023071701351345000_2023.07.10.23292453v1.52","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1001\/jama.2021.21182","article-title":"Heterogeneous State Cannabis Policies: Potential Implications for Patients and Health Care Professionals","volume":"326","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"2023071701351345000_2023.07.10.23292453v1.53","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13011-021-00359-w","article-title":"Cyber-ethnography of cannabis marketing on social media","volume":"16","year":"2021","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"2023071701351345000_2023.07.10.23292453v1.54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.15288\/jsad.2022.83.27","article-title":"A Content Analysis of Cannabis Company Adherence to Marketing Requirements in Four States","volume":"83","year":"2022","journal-title":"J Stud Alcohol Drugs"},{"key":"2023071701351345000_2023.07.10.23292453v1.55","unstructured":"Centers for Disease Control and Prevention. U.S. Opioid Dispensing Rate Maps Centers for Disease Control and Prevention 2021 [Available from: https:\/\/www.cdc.gov\/drugoverdose\/rxrate-maps\/index.html."},{"key":"2023071701351345000_2023.07.10.23292453v1.56","doi-asserted-by":"crossref","unstructured":"Sandbrink F , Murphy JL , Johansson M , Olson JL , Edens E , Clinton-Lont J , et al. The Use of Opioids in the Management of Chronic Pain: Synopsis of the 2022 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Ann Intern Med. 2023.","DOI":"10.7326\/M22-2917"},{"key":"2023071701351345000_2023.07.10.23292453v1.57","unstructured":"Facts About Medical Cannabis 2022 [Available from: https:\/\/medicalcardexam.com\/about-medical-cannabis\/."},{"key":"2023071701351345000_2023.07.10.23292453v1.58","unstructured":"Lutz J. The Empowered Pain Patient\u2019s Guide to Medical Marijuana: Remedy Health Media; 2021 [Available from: https:\/\/patient.practicalpainmanagement.com\/treatments\/medical-marijuana-pain-what-use-for."},{"issue":"3","key":"2023071701351345000_2023.07.10.23292453v1.59","doi-asserted-by":"crossref","first-page":"e222106","DOI":"10.1001\/jamanetworkopen.2022.2106","article-title":"Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults: A Randomized Clinical Trial","volume":"5","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2023071701351345000_2023.07.10.23292453v1.60","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jamainternmed.2019.7517","article-title":"Trends in Cannabis Use Among Older Adults in the United States, 2015-2018","volume":"180","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"12","key":"2023071701351345000_2023.07.10.23292453v1.61","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/acr.24752","article-title":"Increase in Cannabis Use Among Adults With Rheumatic Diseases: Results From a 2014-2019 United States Observational Study","volume":"74","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"3","key":"2023071701351345000_2023.07.10.23292453v1.62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022","volume":"71","year":"2022","journal-title":"MMWR Recomm Rep"},{"key":"2023071701351345000_2023.07.10.23292453v1.63","unstructured":"Pain Management Best Practices Inter-Agency Task Force. Pain Management Best Practices 2019 [Available from: https:\/\/www.hhs.gov\/sites\/default\/files\/pain-mgmt-best-practices-draft-final-report-05062019.pdf."},{"issue":"11","key":"2023071701351345000_2023.07.10.23292453v1.64","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2023071701351345000_2023.07.10.23292453v1.65","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S149262"},{"issue":"1-2","key":"2023071701351345000_2023.07.10.23292453v1.66","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jpain.2019.06.002","article-title":"Examining the Adjustment Patterns of Adults With Multiple Chronic Pain Conditions and Multiple Pain Sites: More Pain, No Gain","volume":"21","year":"2020","journal-title":"J Pain"},{"key":"2023071701351345000_2023.07.10.23292453v1.67","doi-asserted-by":"crossref","unstructured":"Mannes ZL , Stohl M , Fink DS , Olfson M , Keyes KM , Martins SS , et al. Non-pharmacological Treatment for Chronic Pain in US Veterans Treated Within the Veterans Health Administration: Implications for Expansion in US Healthcare Systems. J Gen Intern Med. 2022.","DOI":"10.1007\/s11606-021-07370-8"},{"key":"2023071701351345000_2023.07.10.23292453v1.68","unstructured":"Fink DS , Stohl M , Mannes ZL , Shmulewitz D , Wall M , Gutkind S , et al. Comparing mental and physical health of U.S. veterans by VA healthcare use: Implications for generalizability of research in the VA electronic health records. BMC Health Serv Res. in press."},{"key":"2023071701351345000_2023.07.10.23292453v1.69","doi-asserted-by":"crossref","unstructured":"Meffert BN , Morabito DM , Sawicki DA , Hausman C , Southwick SM , Pietrzak RH , et al. US Veterans Who Do and Do Not Utilize Veterans Affairs Health Care Services: Demographic, Military, Medical, and Psychosocial Characteristics. Prim Care Companion CNS Disord. 2019;21(1).","DOI":"10.4088\/PCC.18m02350"},{"key":"2023071701351345000_2023.07.10.23292453v1.70","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-032315-021353"},{"issue":"1","key":"2023071701351345000_2023.07.10.23292453v1.71","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ajad.12319","article-title":"The epidemiology of substance use disorders in US Veterans: A systematic review and analysis of assessment methods","volume":"25","year":"2016","journal-title":"Am J Addict"},{"key":"2023071701351345000_2023.07.10.23292453v1.72","unstructured":"Center for Behavioral Health Statistics and Quality. Results from the 2019 National Survey on Drug Use and Health: Detailed tables (Table 5.1B) Rockville, MD: Substance Abuse and Mental Health Services Administration; 2020 [Available from: https:\/\/www.samhsa.gov\/data\/."},{"key":"2023071701351345000_2023.07.10.23292453v1.73","doi-asserted-by":"publisher","DOI":"10.1002\/pam.21804"},{"issue":"3","key":"2023071701351345000_2023.07.10.23292453v1.74","doi-asserted-by":"crossref","first-page":"e212545","DOI":"10.1001\/jamanetworkopen.2021.2545","article-title":"Cannabis Policy Heterogeneity and Effects on Research-Complexity Expected","volume":"4","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2023071701351345000_2023.07.10.23292453v1.75","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/add.14985","article-title":"Commentary on Bae & Kerr (2020): Recreational marijuana legalization-we need to think about heterogeneity of policy effects","volume":"115","year":"2020","journal-title":"Addiction"},{"key":"2023071701351345000_2023.07.10.23292453v1.76","doi-asserted-by":"crossref","first-page":"104159","DOI":"10.1016\/j.jpubeco.2020.104159","article-title":"Federalism, partial prohibition, and cross-border sales: Evidence from recreational marijuana","volume":"187","year":"2020","journal-title":"J Public Econ"},{"issue":"12","key":"2023071701351345000_2023.07.10.23292453v1.77","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jpain.2019.05.006","article-title":"Development and Assessment of a Crosswalk Between ICD-9-CM and ICD-10-CM to Identify Patients with Common Pain Conditions","volume":"20","year":"2019","journal-title":"J Pain"},{"issue":"1","key":"2023071701351345000_2023.07.10.23292453v1.78","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1146\/annurev-economics-080217-053402","article-title":"Econometric Methods for Program Evaluation","volume":"10","year":"2018","journal-title":"Annu Rev Econom"},{"issue":"1","key":"2023071701351345000_2023.07.10.23292453v1.79","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1146\/annurev-economics-051520-015456","article-title":"The Econometric Model for Causal Policy Analysis","volume":"14","year":"2022","journal-title":"Annu Rev Econom"},{"key":"2023071701351345000_2023.07.10.23292453v1.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.03.012"},{"issue":"5","key":"2023071701351345000_2023.07.10.23292453v1.81","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2105\/AJPH.2018.304392","article-title":"The C-Word: The More We Discuss It, the Less Dirty It Sounds","volume":"108","year":"2018","journal-title":"Am J Public Health"},{"issue":"4","key":"2023071701351345000_2023.07.10.23292453v1.82","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/ALN.0000000000003067","article-title":"Cannabis Use Disorder and Perioperative Outcomes in Major Elective Surgeries: A Retrospective Cohort Analysis","volume":"132","year":"2020","journal-title":"Anesthesiology"},{"issue":"4","key":"2023071701351345000_2023.07.10.23292453v1.83","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jvs.2020.07.094","article-title":"Cannabis use disorder and perioperative outcomes in vascular surgery","volume":"73","year":"2021","journal-title":"J Vasc Surg"},{"key":"2023071701351345000_2023.07.10.23292453v1.84","doi-asserted-by":"crossref","unstructured":"Jain S , Cloud GW , Gordon AM , Lam AW , Vakharia RM , Saleh A , et al. Cannabis Use Disorder Is Associated With Longer In-Hospital Lengths of Stay, Higher Rates of Medical Complications, and Costs of Care Following Primary 1-to 2-Level Lumbar Fusion. Global Spine J. 2022:21925682221093965.","DOI":"10.1177\/21925682221093965"},{"key":"2023071701351345000_2023.07.10.23292453v1.85","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-016-0595-z"},{"key":"2023071701351345000_2023.07.10.23292453v1.86","doi-asserted-by":"publisher","DOI":"10.1037\/0022-006X.4.2.307"},{"key":"2023071701351345000_2023.07.10.23292453v1.87","unstructured":"Klein H , Bentivegna MC . Cannabis Industry Trends for 2022: Eisner Advisory Group LLC; 2022 [Available from: https:\/\/www.eisneramper.com\/cannabis-trends-0422\/."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.07.10.23292453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:36:55Z","timestamp":1768505815000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.07.10.23292453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":87,"URL":"https:\/\/doi.org\/10.1101\/2023.07.10.23292453","relation":{},"subject":[],"published":{"date-parts":[[2023,7,12]]},"subtype":"preprint"}}